Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Free Cash Flow (2016 - 2025)

Neurocrine Biosciences' Free Cash Flow history spans 16 years, with the latest figure at $386.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 42.63% year-over-year to $386.8 million; the TTM value through Dec 2025 reached $780.5 million, up 31.57%, while the annual FY2025 figure was $780.5 million, 31.57% up from the prior year.
  • Free Cash Flow reached $386.8 million in Q4 2025 per NBIX's latest filing, up from $250.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $386.8 million in Q4 2025 to a low of -$125.8 million in Q1 2023.
  • Average Free Cash Flow over 5 years is $116.9 million, with a median of $116.8 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: soared 4792.31% in 2022, then tumbled 161.54% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $2.6 million in 2021, then skyrocketed by 4792.31% to $127.2 million in 2022, then rose by 13.13% to $143.9 million in 2023, then surged by 88.46% to $271.2 million in 2024, then surged by 42.63% to $386.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Free Cash Flow are $386.8 million (Q4 2025), $250.1 million (Q3 2025), and $89.5 million (Q2 2025).